Physician profile
Anastasios Manessis
NPI 1467615823
$656,431.01
in general payments reported to CMS, 2019-2025
77 companies · $175K in 2025
The $175K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $82K · 2020: $63K · 2021: $61K · 2022: $96K · 2023: $90K · 2024: $90K · 2025: $175K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $284K · Consulting Fee: $27K · Food and Beverage: $23K · Travel and Lodging: $18K · Honoraria: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $283,784.95 |
| Consulting Fee | $27,491.25 |
| Food and Beverage | $23,337.40 |
| Travel and Lodging | $17,998.88 |
| Honoraria | $1,400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $180,068.48 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $160,373.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Ascendis Pharma Endocrinology INC | $72,759.34 | 2023-2025 | Yorvipath |
| Sanofi-Aventis U.S. LLC | $69,715.86 | 2019-2025 | |
| Mannkind Corporation | $56,241.63 | 2019-2025 | Afrezza |
| Astrazeneca Pharmaceuticals Lp | $36,020.75 | 2019-2024 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28,207.11 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $12,326.94 | 2019-2021 | |
| Amgen INC. | $8,062.37 | 2019-2025 | Uplizna, Tepezza, Repatha |
| Amryt Pharma Holdings Ltd | $6,987.41 | 2021-2023 | Mycapssa, Myalept |
| Vistapharm, INC. | $3,487.90 | 2021 | |
| Corcept Therapeutics | $3,347.20 | 2021-2025 | Korlym |
| Medtronic Minimed, INC. | $1,687.72 | 2019 | |
| Abbott Laboratories | $1,600.72 | 2019-2025 | Freestyle Libre 3 |
| Pfizer INC. | $1,524.13 | 2019-2025 |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,465.67 | 2020-2023 | Tepezza |
| Abbvie INC. | $1,357.60 | 2020-2025 | |
| Tandem Diabetes Care, INC. | $1,087.49 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $939.36 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Medtronic, INC. | $802.83 | 2021-2025 | Minimed 780g, Inceptiv |
| Senseonics, Incorporated | $593.00 | 2019-2024 | Eversense |
| Antares Pharma, INC. | $560.55 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Ascensia Diabetes Care US INC. | $527.74 | 2021-2025 | |
| Dexcom, INC. | $465.22 | 2020-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $459.11 | 2019-2025 | Omnipod |
| Amarin Pharma, INC. | $435.41 | 2019-2022 | |
| Astellas Pharma US INC | $430.10 | 2023-2025 | Veozah |
| Intuity Medical INC | $423.20 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Kowa Pharmaceuticals America, INC. | $332.23 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $303.60 | 2021-2024 | Unithroid |
| Eli Lilly and Company | $299.70 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $299.61 | 2020-2023 | Steglatro, Steglujan |
| Cequr Corporation | $274.17 | 2022-2025 | Cequr Simplicity |
| Lifescan, INC. | $239.94 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $227.52 | 2022-2024 | |
| Radius Health, INC. | $173.67 | 2019-2024 | |
| Intra-Sana Laboratories | $151.73 | 2023-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Sequel Med Tech, LLC | $134.63 | 2024 | |
| Currax Pharmaceuticals LLC | $122.85 | 2022-2025 | Contrave |
| Janssen Scientific Affairs, LLC | $122.57 | 2019 | |
| Novartis Pharmaceuticals Corporation | $113.09 | 2021-2024 | |
| Ultragenyx Pharmaceutical INC. | $109.28 | 2021-2025 | Dojolvi |
| Lexicon Pharmaceuticals, INC. | $106.80 | 2024 | |
| Recordati_rare_diseases_inc. | $101.88 | 2022-2025 | Isturisa |
| Becton, Dickinson and Company | $99.93 | 2021-2022 | |
| Ibsa Pharma INC. | $95.23 | 2020-2023 | Tirosint, Licart |
| Eusa Pharma (US) LLC | $84.70 | 2022 | |
| Theratechnologies INC. | $81.37 | 2022 | |
| Madrigal Pharmaceuticals | $76.65 | 2025 | Rezdiffra |
| Amphastar Pharmaceuticals, INC. | $73.13 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $69.73 | 2022 | |
| Endo Pharmaceuticals INC. | $67.73 | 2021 | |
| Zealand Pharma US, INC. | $67.08 | 2020-2021 | |
| Grt US Holding, INC. | $61.65 | 2022 | |
| Treace Medical Concepts, INC. | $54.77 | 2022 | |
| Chiesi USA, INC. | $50.57 | 2024-2025 | Mycapssa |
| Emd Serono, INC. | $48.37 | 2023-2024 | Serostim |
| Eisai INC. | $45.37 | 2022-2023 | |
| Halozyme INC | $38.01 | 2023 | |
| Tolmar, INC. | $36.33 | 2025 | Jatenzo |
| Nevro Corp. | $34.66 | 2022 | |
| Beta Bionics, INC. | $34.60 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Acerus Pharmaceuticals Corporation | $32.97 | 2021-2022 | |
| Aytu Biopharma, INC. | $31.34 | 2019 | |
| Genzyme Corporation | $22.22 | 2022 | |
| Neurocrine Biosciences, INC. | $21.39 | 2024 | |
| Averitas Pharma INC. | $21.25 | 2023 | Qutenza |
| Alexion Pharmaceuticals, INC. | $21.05 | 2021 | |
| Esperion Therapeutics, INC. | $20.97 | 2025 | Nexletol |
| Valeritas, INC. | $18.64 | 2019 | |
| Vivus LLC | $17.11 | 2024 | Qsymia |
| Companion Medical, INC. | $16.32 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.04 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$125,646.53 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anastasios Manessis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.